Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Clinical
Effects of COVID-19 on Vaccine-Preventable Disease Surveillance Systems in the World Health Organization African Region, 2020
John Paul Bigouette
, Anna W. Callaghan, Morgane Donadel, Angela Montesanti Porter, Louie Rosencrans, Jacquelyn S. Lickness, Sara Blough, Xi Li, Robert T. Perry, A.J. Williams, Heather M. Scobie, Benjamin A. Dahl, Jeffrey McFarland, and Christopher S. Murrill
, Anna W. Callaghan, Morgane Donadel, Angela Montesanti Porter, Louie Rosencrans, Jacquelyn S. Lickness, Sara Blough, Xi Li, Robert T. Perry, A.J. Williams, Heather M. Scobie, Benjamin A. Dahl, Jeffrey McFarland, and Christopher S. Murrill
Table 2
Impact of COVID-19 on measles and rubella, AFP/polio, and other VPD surveillance systems according to 154 STOP Program consultants in the World Health Organization’s African Region, 2020*
| Category | No. (%) respondents |
||
|---|---|---|---|
| Measles and rubella | AFP/polio | Other VPDs | |
| Compared to 2019, in 2020 did COVID-19 impact surveillance overall? | |||
| Severely impacted | 66 (43) | 66 (43) | 38 (25) |
| Somewhat impacted | 83 (54) | 84 (55) | 92 (60) |
| Not at all impacted | 3 (2) | 3 (2) | 15 (10) |
| Does not know | 2 (1) | 1 (1) | 9 (6) |
| Missing response |
0 |
0 |
0 |
| Compared to 2019, in 2020 did you conduct active surveillance? | |||
| Increased active surveillance | 3 (2) | 1 (1) | 2 (1) |
| Same level of active surveillance | 21 (14) | 19 (12) | 24 (16) |
| Decreased active surveillance | 108 (70) | 119 (77) | 100 (65) |
| No active surveillance | 20 (13) | 13 (8) | 24 (16) |
| Does not know | 0 | 0 | 0 |
| Missing response |
2 (1) |
2 (1) |
4 (3) |
| Compared to 2019, in 2020 did staffing change for surveillance at your level of responsibility? | |||
| Staffing increased | 4 (2) | 11 (7) | 4 (3) |
| No change in staffing | 103 (67) | 89 (58) | 107 (69) |
| Staffing decreased | 23 (15) | 31 (20) | 24 (16) |
| Does not know | 23 (15) | 22 (14) | 18 (12) |
| Missing response |
1 (1) |
1 (1) |
1 (1) |
| Compared to 2019, in 2020 did COVID-19 impact adversely the detection, notification and reporting of cases? | |||
| Yes | 94 (61) | 106 (69) | 94 (61) |
| No | 37 (24) | 40 (26) | 39 (25) |
| Does not know | 22 (14) | 7 (5) | 20 (13) |
| Missing response |
1 (1) |
1 (1) |
1 (1) |
| For responses indicating an adverse impact on the detection, notification, and reporting of VPD cases, identify the health care level impacted (select all that apply) | |||
| At the national level | 24 (26) | 37 (35) | 29 (30) |
| At the province level | 40 (43) | 50 (47) | 45 (48) |
| At the district level | 75 (80) | 81 (76) | 72 (77) |
| At the local level |
86 (92) |
92 (87) |
85 (90) |
| Compared to 2019, in 2020 did COVID-19 mitigation efforts disrupt the transport of specimens of suspected VPD cases to relevant who reference laboratories? | |||
| Yes | 50 (32) | 73 (47) | 42 (27) |
| No | 50 (32) | 36 (23) | 44 (29) |
| Does not know | 52 (34) | 44 (29) | 66 (43) |
| Missing response | 2 (1) | 1 (1) | 2 (1) |
*AFP, acute flaccid paralysis, VPD, vaccine-preventable disease.
†Percentages may not equal 100% because of rounding.
Page created: August 25, 2022
Page updated: December 11, 2022
Page reviewed: December 11, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.